{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:06:54Z","timestamp":1790687214873,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/01.mjt.0000433951.09030.5a","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T09:14:06Z","timestamp":1385543646000},"page":"e521-e530","source":"Crossref","is-referenced-by-count":94,"title":["Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis"],"prefix":"10.1097","volume":"23","author":[{"given":"Shanshan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-24-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/00365540802298079","article-title":". Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases A clinical descriptive study.","volume":"41","author":"Tabarsi","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"R4-24-20210202","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(04)15496-2","article-title":". Programmes and principles in treatment of multidrug-resistant tuberculosis.","volume":"363","author":"Mukherjee","year":"2004","journal-title":"Lancet"},{"key":"R6-24-20210202","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/MJT.0b013e3181c0806d","article-title":". Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.","volume":"18","author":"Baghaei","year":"2011","journal-title":"Am J Ther"},{"key":"R7-24-20210202","first-page":"275","article-title":". Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.","volume":"14","author":"Bloss","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-24-20210202","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":". Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort.","volume":"16","author":"Carroll","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R9-24-20210202","first-page":"1373","article-title":". Side effects associated with the treatment of multidrug-resistant tuberculosis.","volume":"9","author":"Torun","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"R10-24-20210202","first-page":"648","article-title":". Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis.","volume":"5","author":"Furin","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"R11-24-20210202","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"Society, Centers for Disease Control and Prevention (CDC), Infectious Diseases Society. Treatment of tuberculosis.","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-24-20210202","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(05)17786-1","article-title":". Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.","volume":"365","author":"Leimane","year":"2005","journal-title":"Lancet"},{"key":"R13-24-20210202","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1179\/acb.2009.020","article-title":". Multidrug-resistant tuberculosis: a review of the 23 cases treated by the Saint-Pierre University Hospital (Brussels).","volume":"64","author":"Jacob","year":"2009","journal-title":"Acta Clin Belg"},{"key":"R14-24-20210202","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/QAI.0b013e31821190a3","article-title":". Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients.","volume":"57","author":"Kvasnovsky","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-24-20210202","doi-asserted-by":"crossref","first-page":"e40781","DOI":"10.1371\/journal.pone.0040781","article-title":". Adverse events among HIVMDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.","volume":"7","author":"Isaakidis","year":"2012","journal-title":"PLoS One"},{"key":"R16-24-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R17-24-20210202","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":". Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R18-24-20210202","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":". Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R20-24-20210202","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.","volume":"14","author":"Kunst","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"R21-24-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":". Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R22-24-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":". An official ATS statement: hepatotoxicity of antituberculosis therapy.","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-24-20210202","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(08)61204-0","article-title":". Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study.","volume":"372","author":"Keshavjee","year":"2008","journal-title":"Lancet"},{"key":"R24-24-20210202","first-page":"750","article-title":". Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006.","volume":"12","author":"Masjedi","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"R25-24-20210202","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijantimicag.2006.11.023","article-title":". An intervention programme for the management of multidrug-resistant tuberculosis in France.","volume":"29","author":"Uffredi","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R26-24-20210202","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1378\/chest.124.4.1476","article-title":". Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.","volume":"124","author":"Yew","year":"2003","journal-title":"Chest"},{"key":"R27-24-20210202","first-page":"778","article-title":". Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.","volume":"8","author":"Palmero","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R28-24-20210202","first-page":"1129","article-title":". Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.","volume":"5","author":"Kim","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"R29-24-20210202","doi-asserted-by":"crossref","first-page":"e7186","DOI":"10.1371\/journal.pone.0007186","article-title":". Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.","volume":"4","author":"Seung","year":"2009","journal-title":"PLoS One"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.mjt.0000433951.09030.5a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:28:47Z","timestamp":1620941327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201603000-00024"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mjt.0000433951.09030.5a","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}